– Q1 Revenue was $8.6 Million, Gross Income $2.5 Million and Net Income $0.5 Million – – Construction Pipeline Totals $750 Million, Including ~ 4,200 Residential Development Units – – Company Projects Positive Cash Flow for 2022 – – Management to Host Conference Call Today at 4:30 p.m. ET – JACKSONVILLE.… Read More..

Includes thermostabilized Ebola vaccines Includes nanoemulsion adjuvant compatible with lyophilization PRINCETON, N.J. , May 23, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States Patent… Read More..

Quoin obtains option to exclusive global rights to product; no upfront or milestone fees ASHBURN, Va., May 23, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced it has signed a second, exclusive research… Read More..